Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Bristol-Myers Squibb Stock Holds Near Consensus Target Amid Patent Suit

Guavy AI Editorial Team
Instruments
AMGN
Share

Bristol-Myers Squibb's stock price held near its consensus target of $66.33 on September 14, 2026, closing at $64.08 on the New York Stock Exchange.

The company's shares are trading about 3.5% below their prevailing analyst consensus price target, according to MarketBeat data.

Bristol-Myers Squibb currently carries a Moderate Buy consensus rating, with a non-GAAP EPS guidance in a range of $6.75 to $7.00 for FY 2026 and a consensus estimate of $6.95 per share.

The company has filed a patent suit against Amgen over its proposed biosimilar version of Opdivo, the company's blockbuster cancer immunotherapy drug.

More on Stocks

Stocks just now

Cisco Email Gateway Flaw Actively Exploited, Patch Urged Immediately

Stocks 1m ago

Cisco Secure Email Zero-Day Exploited for Root Access

Stocks 1m ago

Cisco Patches Critical Vulnerability in Secure Email Gateway

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy